159 related articles for article (PubMed ID: 21989411)
41. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
42. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
43. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
44. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
45. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
[TBL] [Abstract][Full Text] [Related]
46. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
[TBL] [Abstract][Full Text] [Related]
47. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
[TBL] [Abstract][Full Text] [Related]
48. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer.
Tilkin AF; Lubin R; Soussi T; Lazar V; Janin N; Mathieu MC; Lefrère I; Carlu C; Roy M; Kayibanda M
Eur J Immunol; 1995 Jun; 25(6):1765-9. PubMed ID: 7615005
[TBL] [Abstract][Full Text] [Related]
49. Interdisciplinary analysis of HIV-specific CD8+ T cell responses against variant epitopes reveals restricted TCR promiscuity.
Hoof I; Pérez CL; Buggert M; Gustafsson RK; Nielsen M; Lund O; Karlsson AC
J Immunol; 2010 May; 184(9):5383-91. PubMed ID: 20363973
[TBL] [Abstract][Full Text] [Related]
50. An MVA vaccine overcomes tolerance to human p53 in mice and humans.
Song GY; Gibson G; Haq W; Huang EC; Srivasta T; Hollstein M; Daftarian P; Wang Z; Diamond D; Ellenhorn JD
Cancer Immunol Immunother; 2007 Aug; 56(8):1193-205. PubMed ID: 17219151
[TBL] [Abstract][Full Text] [Related]
51. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
52. Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy.
Rasmussen S; Donskov F; Pedersen JW; Wandall HH; Buus S; Harndahl M; Braendstrup P; Claesson MH; Pedersen AE
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):487-96. PubMed ID: 23802595
[TBL] [Abstract][Full Text] [Related]
53. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM; Pedersen AE; Johansen JS; Johnsen HE; Nielsen D; Kamby C; Ottesen S; Balslev E; Gaarsdal E; Nikolajsen K; Claesson MH
Cancer Immunol Immunother; 2007 Sep; 56(9):1485-99. PubMed ID: 17285289
[TBL] [Abstract][Full Text] [Related]
54. Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer.
Ferriès E; Connan F; Pagès F; Gaston J; Hagnéré AM; Vieillefond A; Thiounn N; Guillet J; Choppin J
Hum Immunol; 2001 Aug; 62(8):791-8. PubMed ID: 11476902
[TBL] [Abstract][Full Text] [Related]
55. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface.
Lubin R; Schlichtholz B; Bengoufa D; Zalcman G; Trédaniel J; Hirsch A; Caron de Fromentel C; Preudhomme C; Fenaux P; Fournier G; Mangin P; Laurent-Puig P; Pelletier G; Schlumberger M; Desgrandchamps F; Le Duc A; Peyrat JP; Janin N; Bressac B; Soussi T
Cancer Res; 1993 Dec; 53(24):5872-6. PubMed ID: 8261396
[TBL] [Abstract][Full Text] [Related]
56. Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.
Tsuji T; Matsuzaki J; Ritter E; Miliotto A; Ritter G; Odunsi K; Old LJ; Gnjatic S
PLoS One; 2011; 6(8):e23651. PubMed ID: 21858191
[TBL] [Abstract][Full Text] [Related]
57. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
[TBL] [Abstract][Full Text] [Related]
58. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.
Fedoseyeva EV; Boisgérault F; Anosova NG; Wollish WS; Arlotta P; Jensen PE; Ono SJ; Benichou G
J Immunol; 2000 Jun; 164(11):5641-51. PubMed ID: 10820239
[TBL] [Abstract][Full Text] [Related]
59. In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer.
Baloria U; Akhoon BA; Gupta SK; Sharma S; Verma V
Amino Acids; 2012 Apr; 42(4):1349-60. PubMed ID: 21229277
[TBL] [Abstract][Full Text] [Related]
60. CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.
Andrade Filho PA; Ito D; Deleo AB; Ferris RL
Cancer Immunol Immunother; 2010 Oct; 59(10):1561-8. PubMed ID: 20577877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
